Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.04 (market cap $9.43B), while Vanguard Total Stock Market Index Fund ETF trades at $381.89. Which is the better fit depends on your goals.
| BIO | VTI | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | — |
52-Week High | $356.25 | $381.78 |
52-Week Low | $241.71 | $311.68 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
VTI trades at $381.85, up 0.06% with a bullish technical signal from moving averages. The ETF maintains broad diversification across 3,500+ US stocks with a low 0.03% expense ratio. Recent institutional activity shows mixed positioning with some firms increasing holdings while others reduced exposure.
The outlook remains positive given VTI's role as a core total market holding, though the elevated RSI suggests potential near-term consolidation. Key risks include market concentration in large-cap tech and broader economic volatility affecting overall equity performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
